Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment symbols : SNYNF save search
Genentech’s ALK Inhibitor First Adjuvant Treatment for ALK-Positive, Early NSCLC
Published: 2024-04-19 (Crawled : 15:00) - biospace.com/
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: -0.4%
H: 3.01%
C: 2.94%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.83%
H: 1.35%
C: 1.2%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.39%
H: 1.69%
C: 1.23%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
first treatment for
Progressive Familial Intrahepatic Cholestasis Treatment Market Projected to Reach $156.14 million by 2030 - Exclusive Report by 360iResearch
Published: 2024-04-19 (Crawled : 02:00) - prnewswire.com
TAK | News | $13.24 0.61% 0.0% 1.3M
|
Health Technology
|
| O: 0.23%
H: 0.61%
C: 0.46%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.83%
H: 1.83%
C: 0.89%
MIRM | News | $23.83 1.1% 1.09% 340K
|
Health Technology
|
| O: -0.68%
H: 2.52%
C: 1.71%
report million reach treatment market
Prostate Cancer: Advancements in Prevention and Treatment Drive Global Market Growth
Published: 2024-04-17 (Crawled : 09:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: 0.12%
H: 0.51%
C: 0.51%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.04%
H: 0.28%
C: -0.16%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.05%
H: 0.0%
C: 0.0%
treatment global growth market
Innovent and HUTCHMED Jointly Announce NDA Acceptance in China for Sintilimab Combination with Fruquintinib for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
review cancer treatment advanced china
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
Published: 2024-04-02 (Crawled : 05:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.79%
H: 1.32%
C: 1.18%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.14%
H: 0.02%
C: -1.06%
HCM | $16.49 0.8% 0.79% 61K
|
Health Technology
|
| O: 0.21%
H: 1.49%
C: -0.06%
treatment advanced china
Global Infectious Enteritis Treatment Market Report 2024: A USD$937.7 Million Market by 2034 - Antibiotics Segment Dominates the Market
Published: 2024-03-29 (Crawled : 23:00) - prnewswire.com
ARDX | $6.5 0.93% 0.92% 5.6M
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
| Email alert
Add to watchlist
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
| Email alert
Add to watchlist
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
report million treatment antibiotics global market
Regeneron Hit With Two CRLs, J&J’s PAH Treatment Approved
Published: 2024-03-25 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -100.0%
H: NaN%
C: Infinity%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.35%
H: 0.35%
C: -1.34%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: -0.07%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.42%
H: 0.0%
C: 0.0%
approved treatment
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $39.47 -0.45% 0.0% 2.8M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Global Immune Thrombocytopenia Drug Markets, 2019-2022 and 2023-2029: Advanced Drug Delivery Technologies Transform Management, Second-Generation TPO-RAs Revolutionize Treatment Options
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
drug treatment global advanced
Amyotrophic Lateral Sclerosis Treatment Market size to grow by USD 663.7 million, 42% of market growth is expected in North America, Technavio
Published: 2024-03-12 (Crawled : 04:00) - prnewswire.com
ELDN | $1.85 -7.03% -7.57% 420K
|
Manufacturing
|
| O: 1.73%
H: 1.7%
C: -7.39%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.01%
H: 0.0%
C: 0.0%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: -0.6%
H: 0.74%
C: -3.66%
BCLI A | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: -2.43%
H: 2.8%
C: -4.02%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: -0.32%
H: 0.18%
C: -0.86%
expected sclerosis treatment growth market
Global Hemophilia Market Analysis Report 2023-2028: Increased Focus on Prophylactic Treatment and Shifting Focus to Extended Half Life Therapies
Published: 2024-03-07 (Crawled : 18:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
report life treatment global market
Chemotherapy Induced Peripheral Neuropathy Treatment Market Projected Strong Growth to $2.25 Billion by 2028 Amid Advancements in Cancer Treatment
Published: 2024-03-07 (Crawled : 00:00) - prnewswire.com
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 1.41%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.62%
H: 0.0%
C: 0.0%
QDEL | News M | $39.09 2.17% 2.12% 1.1M
|
Health Technology
|
| O: 1.14%
H: 4.36%
C: 3.16%
AMGN | $269.03 2.39% 2.33% 3.4M
|
Health Technology
|
| O: -0.1%
H: 0.18%
C: -1.25%
cancer treatment growth market
AnHeart Therapeutics and Innovent Announce China’s NMPA has Accepted Second New Drug Application for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 08:00) - biospace.com/
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
lung drug cancer treatment application therapeutics
Innovent and AnHeart Therapeutics Announce the NMPA of China Has Accepted Second NDA for Taletrectinib for First-Line Treatment of ROS1-Positive Lung Cancer
Published: 2024-03-05 (Crawled : 06:00) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.17%
H: 0.0%
C: 0.0%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.4%
H: 0.38%
C: -1.77%
lung cancer treatment therapeutics china
Valo Health Completes Enrollment of OPL-0401 Phase 2 Study for the Treatment of Diabetic Retinopathy
Published: 2024-03-04 (Crawled : 18:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
opl-0401 health treatment study diabetic
FDA Decisions: J&J’s Rybrevant Becomes First Front-Line Treatment for Type of NSCLC
Published: 2024-03-04 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
PRGO | News | $30.8 2.87% -1.14% 1.2M
|
Health Technology
|
| O: 0.65%
H: 1.13%
C: -1.02%
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.42%
H: 0.0%
C: 0.0%
ABT | News | $107.28 1.91% 0.18% 10M
|
Health Technology
|
| O: 0.03%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
fda first treatment rybrevant
ALS Treatment Landscape ‘Primed’ with Over 100 Candidates: GlobalData
Published: 2024-03-04 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.9%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.8%
H: 0.0%
C: 0.0%
als treatment 100
TL1A Inhibitors Could Usher in New Era for IBD Treatment
Published: 2024-02-26 (Crawled : 05:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.89%
H: 0.0%
C: 0.0%
treatment
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.97%
H: 0.0%
C: 0.0%
REGN | $896.27 0.26% 0.25% 500K
|
Health Technology
|
| O: 1.05%
H: 1.09%
C: 0.64%
dupixent fda review treatment copd
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.